Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross‐sectional study of iron‐related magnetic resonance imaging susceptibility

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Neurology

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ene.13208PMID 27982501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI.

  2015cited by this paper
• A multicontrast approach for comprehensive imaging of substantia nigra

  2015cited by this paper
• Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.

  2015cited by this paper
• Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.

  2014cited by this paper
• Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

  2014cited by this paper
• Is R2* a New MRI Biomarker for the Progression of Parkinson’s Disease? A Longitudinal Follow-Up

  2013cited by this paper
• Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease

  2013cited by this paper
• Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD

  2013cited by this paper
• Nigral iron deposition occurs across motor phenotypes of Parkinson’s disease

  2012cited by this paper
• Different Iron-Deposition Patterns of Multiple System Atrophy with Predominant Parkinsonism and Idiopathetic Parkinson Diseases Demonstrated by Phase-Corrected Susceptibility-Weighted Imaging

  2012cited by this paper
• Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration

  2011cited by this paper
• T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease

  2011cited by this paper
• Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X‐ray fluorescence

  2010cited by this paper
• Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults

  2010cited by this paper
• Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.

  2010cited by this paper
• MRI estimates of brain iron concentration in normal aging: Comparison of field-dependent (FDRI) and phase (SWI) methods

  2009cited by this paper
• MRI assessment of basal ganglia iron deposition in Parkinson's disease

  2008cited by this paper
• Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications

  2008cited by this paper
• Midbrain iron content in early Parkinson disease

  2008cited by this paper
• Susceptibility-Weighted Imaging: Technical Aspects and Clinical Applications, Part 1

  2008cited by this paper
• Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain

  2007cited by this paper
• Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease

  2006cited by this paper
• Imaging iron stores in the brain using magnetic resonance imaging.

  2005influential reference
• MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease

  2005cited by this paper
• Susceptibility weighted imaging (SWI)

  2004cited by this paper
• High‐field magnetic resonance imaging of brain iron: birth of a biomarker?

  2004cited by this paper
• The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings.

  2002cited by this paper
• Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour

  2001cited by this paper
• Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.

  2000cited by this paper
• Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro

  1999cited by this paper
• The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

  1999cited by this paper
• Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro.

  1999cited by this paper
• Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

  1997cited by this paper
• Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease.

  1995cited by this paper
• T2 relaxation time in patients with Parkinson's disease

  1993cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

  1991cited by this paper
• Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation.

  1988cited by this paper
• Increased nigral iron content in postmortem parkinsonian brain.

  1987cited by this paper
• Penicillin-sensitive streptococcal endocarditis.

  1982cited by this paper
• Ferritin: structure, biosynthesis, and role in iron metabolism.

  1978cited by this paper
• THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN

  1958influential reference

• Ferroptosis in Parkinson's disease: a review of molecular mechanisms and emerging therapeutic strategies.

  2026cites this paper
• Relationship between reduced serum ceruloplasmin levels and executive dysfunction in hospitalized schizophrenia patients

  2025cites this paper
• Nigrostriatal iron accumulation in the progression of Parkinson’s disease

  2025cites this paper
• From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson’s disease

  2025cites this paper
• Lactoferrin as a Candidate Multifunctional Therapeutic in Synucleinopathies

  2025cites this paper
• Ferroptosis: a novel pathogenesis and therapeutic strategies for Parkinson disease: A review

  2025cites this paper
• Spatiotemporal nigrostriatal iron accumulation in motor subtypes of Parkinson’s disease: from early to late stage

  2025cites this paper
• Iron Deposition in Parkinson’s Disease: A Mini-Review

  2024cites this paper
• Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects

  2024cites this paper
• Postencephalitic Parkinsonism: Unique Pathological and Clinical Features—Preliminary Data

  2024cites this paper
• Microglia in Neurodegenerative Diseases.

  2024cites this paper
• Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis

  2024cites this paper
• Ferroptosis in Parkinson's Disease: Molecular Mechanisms and Therapeutic Potential.

  2023cites this paper
• Deferoxamine Ameliorates Cypermethrin-Induced Iron Accumulation and Associated Alterations

  2023cites this paper
• Distribution pattern of iron deposition in the basal ganglia of different motor subtypes of Parkinson's disease.

  2023cites this paper
• An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders

  2022cites this paper
• Cerebral blood flow regulates iron overload in the cerebral nuclei of hemodialysis patients with anemia

  2022cites this paper
• Nigral neuropathology of Parkinson’s motor subtypes coincide with circuitopathies: a scoping review

  2022cites this paper
• Brain iron deposition and movement disorders in hereditary haemochromatosis without liver failure: A cross‐sectional study

  2022cites this paper
• MRI Signs of Parkinson’s Disease and Atypical Parkinsonism Magnetresonanztomografische Zeichen des idiopathischen Parkinson-Syndroms sowie atypischer Parkinson-Syndrome

  2021cites this paper
• Environmental neurotoxicants and inflammasome activation in Parkinson's disease - a focus on the gut-brain axis.

  2021cites this paper
• Parkinsonism

  2021cites this paper
• Brain regions susceptible to alpha-synuclein spreading

  2021cites this paper
• Lewy Body Dementias: A Coin with Two Sides?

  2021cites this paper
• MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease

  2021cites this paper
• Intracellular Sources of ROS/H2O2 in Health and Neurodegeneration: Spotlight on Endoplasmic Reticulum

  2021cites this paper
• Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?

  2021cites this paper
• MRI: how to understand it

  2021cites this paper
• Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease

  2020cites this paper
• Parkinson’s disease and iron

  2020cites this paper
• Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis

  2020cites this paper
• Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach.

  2020cites this paper
• Different iron deposition patterns in akinetic/rigid-dominant and tremor-dominant Parkinson's disease.

  2020cites this paper
• Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review

  2020cites this paper
• The role of iron in Parkinson's disease monkeys assessed by susceptibility weighted imaging and inductively coupled plasma mass spectrometry.

  2019cites this paper
• Redox active metals in neurodegenerative diseases

  2019cites this paper
• Quantifying iron content in magnetic resonance imaging

  2019cites this paper
• The Association of Iron and the Pathologies of Parkinson’s Diseases in MPTP/MPP+-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture

  2019cites this paper
• Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities

  2019cites this paper
• Structural Imaging in Parkinson’s Disease: New Developments

  2019cites this paper
• Regional High Iron in the Substantia Nigra Differentiates Parkinson’s Disease Patients From Healthy Controls

  2019cites this paper
• Iron deposition in Parkinson’s disease by quantitative susceptibility mapping

  2019cites this paper
• From niche methods to necessary tools: The growing importance of analytical atomic spectrometry in metal imaging in neuroscience

  2019cites this paper
• Molecular targets and therapeutic interventions for Iron induced neurodegeneration.

  2019cites this paper
• Brain Iron Accumulation in Atypical Parkinsonian Syndromes: in vivo MRI Evidences for Distinctive Patterns

  2019cites this paper
• Multimodal dopaminergic and free-water imaging in Parkinson's disease.

  2019cites this paper
• Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis

  2019cites this paper
• Neuroinflammation in Neurodegenerative Diseases: Current Multi-modal Imaging Studies and Future Opportunities for Hybrid PET/MRI.

  2019cites this paper
• New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases

  2018cites this paper
• Inflammasomes: An Emerging Mechanism Translating Environmental Toxicant Exposure Into Neuroinflammation in Parkinson's Disease.

  2018cites this paper
• Parkinson's disease related signal change in the nigrosomes 1–5 and the substantia nigra using T2* weighted 7T MRI

  2018cites this paper
• Iron deposition quantification: Applications in the brain and liver

  2018cites this paper
• Neuroimaging advances in Parkinson's disease.

  2018cites this paper
• Progress in neurology 2017–2018

  2018cites this paper
• Alpha-synuclein and iron: two keys unlocking Parkinson’s disease

  2017cites this paper
• The Ceruloplasmin Transferrin Ratio in the Blood of Patients at Different Stages of Parkinson’s Disease

  2017cites this paper
• Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review

  2017cites this paper
• Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper